head and neck cancer

Rakuten’s CEO raises $150M to fund his biotech outfit Aspyrian's cancer photoimmunotherapies
Rakuten’s CEO raises $150M to fund his biotech outfit Aspyrian's cancer photoimmunotherapies
Fierce Biotech
Rakuten Aspyrian
photoimmunotherapy
head and neck cancer
Flag link:
CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial
CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial
CP Wire
Cel-Sci
Multikine
head and neck cancer
Flag link:
CEL-SCI Gets Independent Recommendation to Continue PH III Head and Neck Cancer Trial
Cel-Sci
Multikine
head and neck cancer
Flag link:
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
Immunicum AB Announces FDA Approval to Expand Ph Ib/II trial of Cancer Drug
CP Wire
Immunicum
clinical trials
ilixadencel
head and neck cancer
non-small cell lung cancer
gastric cancer
Flag link:
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
Seattle Genetics Doses First Patient In Ph II Trial of Antibody-drug Conjugate in Multiple Solid Tumors
CP Wire
Seattle Genetics
colorectal cancer
non-small cell lung cancer
pancreatic cancer
head and neck cancer
cervical cancer
tisotumab vedotin
Genmab
clinical trials
Flag link:
Innovation Pharmaceuticals Reports on Successful Phase II Trial of Brilacidin-OM for Oral Mucositis
Innovation Pharmaceuticals Reports on Successful Phase II Trial of Brilacidin-OM for Oral Mucositis
CP Wire
Innovation Pharmaceuticals
Brilacidin-OM
head and neck cancer
severe oral mucositis
Flag link:
On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo
Endpoints
Regeneron
ISA
cervical cancer
head and neck cancer
cemiplimab
Flag link:
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Can Pfizer Bank on New Immunotherapy Bavencio for Growth?
Yahoo/Zacks.com
Pfizer
Bavencio
immuno-oncology
renal cell carcinoma
lung cancer
ovarian cancer
head and neck cancer
Flag link:
FDA gives OK, Cel-Sci clinical hold finally lifted
FDA gives OK, Cel-Sci clinical hold finally lifted
BioPharma Dive
FDA
Cell-Sci
Multikine
clinical trials
head and neck cancer
Flag link:
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer
Xconomy
Merck
Keytruda
head and neck cancer
Flag link:
Bristol-Myers' Opdivo racks up latest NICE rejection, this time in head and neck cancer
Bristol-Myers' Opdivo racks up latest NICE rejection, this time in head and neck cancer
Fierce Pharma
Bristol-Myers Squibb
Opdivo
NICE
head and neck cancer
Flag link:
Bristol's Bid To Get Ahead In Head And Neck
Bristol's Bid To Get Ahead In Head And Neck
Seeking Alpha
Bristol-Myers Squibb
head and neck cancer
Opdivo
Keytruda
Merck
Flag link:
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
FDA slaps a partial hold on one of AstraZeneca’s crucial durvalumab programs
Endpoints
FDA
AstraZeneca
durvalumab
clinical trials
head and neck cancer
Flag link:
How Pfizer Plans to Extend Ibrance beyond Breast Cancer Treatment
How Pfizer Plans to Extend Ibrance beyond Breast Cancer Treatment
Market Realist
Pfizer
Ibrance
breast cancer
head and neck cancer
lung cancer
pancreatic cancer
Flag link:
Bristol-Myers's Opdivo Extends Survival in Head, Neck Cancer
Bristol-Myers's Opdivo Extends Survival in Head, Neck Cancer
Bloomberg
Bristol-Myers Squibb
Opdivo
head and neck cancer
Flag link:
Keytruda, Opdivo near new cancer uses where they won't butt heads
Keytruda, Opdivo near new cancer uses where they won't butt heads
Fierce Pharma
Keytruda
Opdivo
Bristol-Myers Squibb
Merck
Hodgkin's lymphoma
head and neck cancer
Flag link:
Cel-Sci's Enrollment Math Doesn't Add up
Cel-Sci's Enrollment Math Doesn't Add up
TheStreet.com
head and neck cancer
Cel-Sci
Multikine
Flag link:
First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
First Presentation of Early Data for Pembrolizumab (MK-3475), Merck’s Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014
Yahoo/BusinessWire
Pembrolizumab
Merck
head and neck cancer
Flag link:
Oncolytics Biotech reports tumor stabilization or shrinkage in REOLYSIN study
Oncolytics Biotech reports tumor stabilization or shrinkage in REOLYSIN study
The Fly on the Wall
Oncolytics
Reolysin
head and neck cancer
Flag link:
Cel-Sci's Multikine - Potential 21st Century Superdrug
Cel-Sci's Multikine - Potential 21st Century Superdrug
Seeking Alpha
Cel-Sci
head and neck cancer
Multikine
Flag link:

Pages